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Abstract 
The 18kDa translocator protein (TSPO) is a marker of microglia activation in the central 
nervous system and represents the main target of radiotracers for the in vivo quantification 
of neuroinflammation with positron emission tomography (PET).  
TSPO PET is methodologically challenging given the heterogeneous distribution of TSPO 
in blood and brain. Our previous studies with the TSPO tracers [11C]PBR28 and 
[11C]PK11195 demonstrated that a model accounting for TSPO binding to the endothelium 
improves the quantification of PET data.  
Here we performed a validation of the kinetic model with the additional endothelial 
compartment through a displacement study. Seven subjects with schizophrenia, all high-
affinity binders, underwent two [11C]PBR28 PET scans before and after oral administration 
of 90mg of the TSPO ligand XBD173. The addition of the endothelial component provided 
a signal compartmentalization much more consistent with the underlying biology as only in 
this model the blocking study produced the expected reduction in the tracer concentration 
of the specific tissue compartment, whereas the non-displaceable compartment remained 
unchanged.  
In addition, we also studied TSPO expression in vessels using 3D reconstructions of 
histological data of frontal lobe and cerebellum, demonstrating that TSPO positive vessels 
account for 30% of the vascular volume in cortical and white matter. 
 
Keywords 
TSPO, [11C]PBR28, kinetic modelling, endothelium, XBD173, immunohistochemistry,  
3D modelling 
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INTRODUCTION 
The translocator protein (TSPO) is a five transmembrane domain 18 kDa protein 
located in the outer mitochondrial membrane 1. In the brain, the TSPO is upregulated by 
microglial cells and macrophages during the inflammatory response, and to a much less of 
an extent in reactive astrocytes 2, 3. The TSPO therefore represents an ideal target for 
positron emission tomography (PET) studies aimed at imaging neuroinflammation in vivo 4, 
5. 
Quantification of TSPO with PET is challenging regardless of the probe used 6, 7. 
[11C]PK11195 gives a poor signal-to-noise ratio 6 while the use of second-generation TSPO 
tracers is limited by the single nucleotide polymorphism (rs6971) in the TSPO gene 8, which 
affects their binding affinity 9. All TSPO radiotracers can bind plasma proteins, platelets and 
monocytes to various extents and such binding can be altered in pathological conditions 
affecting the peripheral immune system, such as systemic inflammation 10-15. For these 
tracers, free plasma fractions are generally very low (<5%) and difficult to measure 7, 16, a 
matter that complicates further the quantification of image data. The uneven distribution of 
TSPO in the normal brain and its changes that occur in pathological states represent another 
challenge for the quantification of binding and affect the use of reference region approaches. 
Successful methods using the grey matter signal of healthy controls as pseudo-reference 
region have been developed for [11C]PK11195 17 but never replicated with other tracers. 
The expression of TSPO in the endothelium and tunica media of brain vessels 17 
contributes to the background signal observed with [11C]PK11195 and second generation 
tracers and this TSPO fraction in vessels is reduced in aged brains due to fibrosis of the 
vessel walls 18. The contribution of vascular TSPO to the total measurable PET signal is 
expected to be proportional to the affinity of the tracer, hence the high-affinity second 
generation compounds are more likely to be affected by vascular TSPO binding than the 
lower affinity tracers such as [11C]PK11195. We previously proposed a 2TCM-1K model 19 
for the quantification of the second generation ligand [11C]PBR28 20 to account for the 
endothelial component of TSPO. Compared to the standard 2-tissues compartmental model 
(2TCM), 2TMC-1K includes the tracer binding to TSPO in vessels by adding an additional 
compartment in parallel to those describing the tissue tracer activity 19. When applied to 
[11C]PBR28 brain PET data in healthy controls, the 2TCM-1K model provided a statistically 
superior description of the [11C]PBR28 uptake, reducing inter-subject variability but 
preserving the sensitivity for the known changes in affinity displayed by the populations with 
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varying rs6971 genotypes 19 (high affinity binders – HABs; medium affinity binders MAB. 
The low affinity binders – LABS – were not included in the study). In simulations, 2TMC-1K 
also showed higher sensitivity to TSPO tissue changes compared to standard 2TCM 19. The 
distribution volume estimates calculated using the 2TCM-1K model were shown to be better 
correlated with the TSPO mRNA mappings of the Allen Brain Atlas than those of the 
standard 2TCM 19. When used in a [11C]PBR28 brain PET study of subjects with 
schizophrenia, the 2TCM-1K was able to reproduce the same regional findings of previous 
studies that used [11C]PK11195 7, 21. 
This study aims to complete the validation of the 2TCM-1K model by comparing its 
sensitivity to changes in TSPO density with the 2TCM model. 2TCM-1K and 2TCM models 
were applied to data from seven patients with schizophrenia investigated with [11C]PBR28 
PET before and after the administration of a pharmacological dose of the TSPO agonist 
XBD173. The expectation was that in the 2TCM-1K analysis the pharmacological blockade 
would correctly translate to comparable changes in the volume of distribution of the 
compartment describing the ligand specifically bound to TSPO (tissue and endothelial) but 
minimum changes of the compartment associated with the free tracer and non-specifically 
bound tracer fraction (i.e. non-displaceable compartment). In the standard 2TCM we 
expected that changes in the target TSPO would map unpredictably on both the free and 
the bound tracer compartment. The second aim of the study was to profile the effects of 
XBD173 on the concentration of [11C]PBR28 in the free and bound blood components as 
well as its radiometabolites to assess more generally the possibility of accurate 
quantification of pharmacological interventions targeting the TSPO. Finally, we investigated 
the TSPO expression in cortical and white matter vessels in samples of normal frontal lobe 
and cerebellum using immunohistochemistry data reconstructed with both a 2-dimensional 
and 3-dimensional approach.  
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MATERIALS AND METHODS 
 
Datasets 
The data used in this work were part of a study aiming to investigate 
neuroinflammation in schizophrenia with [11C]PBR28 PET imaging. The study was approved 
by the Hammersmith Research Ethics Committee and was conducted in accordance with 
the Declaration of Helsinki. Subjects were given a full description of the study before 
providing written consent. 
Seven males (average age 46±10 years) diagnosed with schizophrenia were 
recruited from SLAM NHS Trust (London) and included in the study. All patients met the 
DSM-V criteria determined by clinical interview and review of the medical records. At the 
moment of PET scanning, patients were under stabilized treatment, all taking standard 
antipsychotics. Compared to baseline scan there was minimum change in antipsychotic 
medications in 5 patients out of 7. On those cases where a change on antipsychotic 
medication occurred, patients kept similar chlorpromazine equivalents. All the subjects were 
also tested for the rs6971 TSPO genetic polymorphism and only homozygote high-affinity 
binders (HABs) were included in the analysis. 
 
Experimental protocol 
Each participant had two PET scans with [11C]PBR28: the first at baseline conditions, 
and the second after XBD173 administration. The two [11C]PBR28 PET scans were 
performed at different days: six out of the seven subjects, previously included in 21, had the 
baseline PET scan approximately 2 years (866±82 days) before the XBD173 scan. Only one 
subject had both baseline and blocked scan within a week of each other. Notably, PET scans 
started at a similar time of day (mean injection time: 14:32; earliest injection:10:46; latest 
injection: 15:56) to reduce intra- and inter-subject variability, limiting the effects of circadian 
rhythms on TSPO density 22, 23. 
All the subjects underwent high-resolution T1 magnetic resonance imaging (MRI) in 
a Siemens Tim Trio 3T scanner (Siemens Healthcare, Erlangen, Germany). These structural 
MRI images were coregistered with the PET imaging to identify the anatomical regions of 
interest. 
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Administration of XBD173 
XBD173 is a selective TSPO agonist developed for the treatment of generalized 
anxiety, and previously tested in occupancy studies 24. All the subjects received an oral dose 
of 90 mg dose of XBD173, corresponding to 0.98±0.16mg/Kg (mean±SD) normalized dose 
based on the patient weight. Assuming an effective dose of 0.34 mg/Kg to reach 50% of 
target occupancy (ED50) 24, the administered dosage of XBD173 aimed to reach between 
66% and 77% of TSPO brain occupancy. The timing of radiotracer injection was also 
designed to match the peak concentration of the drug in blood according to 24. No measure 
of XBD173 plasma concentration was taken during the study to control for individual 
differences in pharmacokinetics.  
 
PET imaging 
An initial low-dose computer tomography (CT) scan was acquired for attenuation and 
scatter correction using Siemens Biograph™ True Point™ PET/CT scanner (Siemens 
Medical Systems, Germany). Subjects then received a bolus injection of [11C]PBR28 (target 
dose ~ 300 Mbq) followed by a 90 minute PET emission scan. PET data were acquired in 
three-dimensional mode and binned into 26 frames (durations: 8 x 15 s, 3 x 1 min, 5 x 2 min, 
5 x 5 min, 5 x 10 min). Images were reconstructed using filtered back projection and 
corrected for attenuation and scatter. Radiopharmaceutical preparation of [11C]PBR28 was 
done as described in 24 and it was consistent with previous studies21. 
In parallel to the PET acquisition, arterial blood was sampled from the radial artery 
using a combined automatic and manual approach. A continuous sampling system (ABSS 
Allogg, Mariefred, Sweden) was used to measure whole blood activity for the first 15 minutes 
of each scan at the rate of one sample per second. Discrete blood samples were manually 
taken at 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 minutes, centrifuged and used to 
determine the plasma over blood activity ratio (POB). Samples at 5, 10 and 15 minutes were 
used to calibrate the two sampling modalities. Samples taken at 5, 10, 20, 30, 50, 70 and 
90 minutes were also analysed using HPLC to calculate the plasma fraction of tracer free of 
metabolites (PPf). Radiometabolite analysis of [11C]PBR28 in the blood was done as 
described previously 21, 24. 
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Image analysis 
Structural MRI images were used for grey/white matter segmentation and region of 
interest (ROI) definition. A neuroanatomical atlas was co-registered on each subject’s MRI 
scan and PET image using a combination of Statistical Parametric Mapping 8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) functions, 
implemented in MIAKATTM (http://www.imanova.co.uk). ROIs included occipital lobe, 
temporal lobe, frontal lobe, parietal lobe, insular cortex, cingulate cortex, amygdala, 
hippocampus, thalamus, striatum and cerebellum.  
All PET images were corrected for head movement using non-attenuation-corrected 
images as they include greater scalp signal, which improves re-alignment compared to 
attenuation-corrected images. Frames were realigned to a single “reference” space 
identified by the PET frame with the highest activity. The transformation parameters were 
then applied to the corresponding attenuation-corrected PET frames to create a movement-
corrected dynamic image for analysis. Regional TACs were obtained by sampling the image 
with the co-registered atlas.  
To investigate the effect of XBD173 on [11C]PBR28 uptake, standardised uptake 
values (SUV), using injected dose and patient weight as normalisation factors, were 
computed 90 minutes after tracer injection for each PET scan. 
 
Blood data processing 
Processing of blood samples was performed consistently with previous studies 21. 
Both POB and PPf were fitted with an extended Hill model 25 that provided the best data 
description 26. Whole blood TACs were fitted using a variation of Feng’s model that consists 
in a straight line to the arterial input function peak followed by a tri-exponential decay 27. For 
each scan, the difference between tracer arrival time in the brain and arterial sampling site 
was estimated by shifting blood curves 0-20 sec (both parent and whole blood TACs), fitting 
the whole brain TAC (using exponential spectral analysis to avoid dependency on a 
particular compartmental model), and selecting the delay that produced the smallest 
weighted residual sum of squares. 
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Kinetic analysis 
Quantification of [11C]PBR28 tissue distribution was performed using both the 2TCM-
1K and the standard 2TCM. Note that these kinetic models share most of the 
microparameters with the exception of 𝐾𝑏 which is explicitly used in 2TCM-1K to account for 
the endothelial TSPO component 19. A summary of the model configurations and kinetic 
parameters is reported in the supplementary material – Figure 1. 
Both 2TCM-1K and 2TCM models were solved using the weighted nonlinear least 
square estimator (WNLLS), as implemented in Matlab2012b (The Mathworks Inc., Natick, 
MA). Initial microparameter values were set based on the literature 19, while weights for the 
individual data points were defined as the inverse of the variance of the PET measurement 
error. This was assumed to be additive, uncorrelated, normally distributed with a zero mean 
and variance equal to the decay-corrected activity divided by the length of the relative scan 
interval, multiplied by a scale factor, estimated a posteriori 28. The total distribution volume 
(𝑉𝑇) was then determined (regions with 𝑉𝑇 estimates higher than 10 mL/cm
3 or with unreliable 
precision (CV>50%) were excluded from the analysis as non-physiological based on 
previous analysis 19). For both models, the blood volume fraction (𝑉𝑏) was estimated together 
with the other model microparameters. 
The comparison between the two models was done first by assessing fit performance 
and data model description efficiency as measured by the Akaike information criterion 
(AIC)29. The two models were then assessed in term of total signal compartmentalisation: 
changes of total distribution volume (𝑉𝑇) before and after blocking were correlated with the 
changes of specific binding (as indicated by 𝑘3 𝑘4⁄ ) and non-displaceable binding (as 
indicated by 𝐾1 𝑘2⁄  ratio). For 2TCM-1K the endothelial binding changes (∆𝐾𝑏) were also 
calculated and compared to changes in the tracer specific binding (𝑘3 𝑘4⁄ ). 
 
Statistical Analysis 
Statistical analysis was conducted in SPSS version 21 (www.spss.com). Two-tailed 
paired t-tests were used to assess whether there were statistically significant differences 
between [11C]PBR28 PET scans at baseline and after XBD173 blockage. Target variables 
of this analysis included experimental settings and tracer dosing, blood and tissue tracer 
uptakes, as well as compartmental modelling kinetic estimates. The Pearson’s linear 
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correlation coefficient was used to test for the presence of any association between 
[11C]PBR28 plasma free fraction and [11C]PBR28 tissue kinetics. 
Variation of 𝑉𝑇 estimates (before and after blocking) for both 2TCM and 2TCM-1K 
were correlated with the TSPO mRNA expression mappings contained in the Allen Human 
Brain Atlas (http://www.brain-map.org)30. We have previously shown that these maps are 
highly predictive of protein levels in-vivo measured with PET for all those transcripts that do 
not undergo significant post-transcriptional modifications 31. We hypothesised that the 
reduction of [11C]PBR28 binding due to XBD173 TSPO blocking would be proportional to 
the TSPO mRNA expression. Changes for SUV, 𝐾1 𝑘2⁄  and 𝑘3 𝑘4⁄  were also considered. 
Processing and analysis of mRNA data were run using the software application MENGA 32. 
 
Assessment of vascular TSPO in normal human brain 
The anterior superior frontal lobe and the cerebellum of three normal brains were 
obtained from the Multiple Sclerosis & Parkinson’s Disease Tissue bank at Imperial College, 
UK. For each case, 10 µm thick sections were cut from formalin fixed paraffin embedded 
(FFPE) tissue blocks. Immunostains were performed using immunoperoxidase and 
immunofluorescence with antibodies directed against the vascular marker CD31, the glial 
fibrillary acidic protein (GFAP) and TSPO. The sections were deparaffinised by heating for 
20 min in an oven at 60°C, 3 x 10 min in 100% xylene, 2 x 5 min in 100 Ethanol, 5 min in 
90% ethanol, 5 min in 70% ethanol and 2 x 5 min in water. For immunoperoxidase, the 
sections were immersed for 20 minutes in steam heated sodium citrate buffer (10mM 
Sodium Citrate, 0.05% v/v Tween 20, pH 6) followed by quenching of endogenous 
peroxidase in methanol and 1% v/v hydrogen peroxide for 15 minutes. The sections were 
thereafter incubated with the primary antibody at the following dilutions: CD31 (Dako Clone 
JC7QA Ref M0823 (1:30), anti-GFAP (Dako Clone 6F2 Ref M0761, dilution 1:200) and anti-
TSPO (Abnova, goat polyclonal; dilution 1:500). The SuperSentitive IHC detection system 
from BioGenex (Fremon, CA, USA) was used the next day for visualisation as per the 
manufacturer’s instructions. Finally sections were counterstained with Mayer’s Haemalum 
before being dehydrated and cover slipped. 
The specificity of the anti-TSPO antibody was tested. Immunoreactions with omission 
of the primary antibody were performed as negative controls and sections of adrenal cortex 
were included in each batch as positive controls. The epitope recognised by the anti-TSPO 
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antibody corresponds to amino acids 158–169, which are unique to human TSPO 
(Blast/Fasta; www.pir.georgetown.edu). A western-blot was also run with total protein 
extracts from human normal adrenal glands that constitutively contain high level of TSPO. 
Results are shown in supplementary material – Figure 2.  
Double immunofluorescence with CD31/TSPO and GFAP/TSPO was carried out as follows. 
A cocktail of both antibodies in donkey serum buffer (PBS + 0.5% v/v donkey serum, 1% 
w/v BSA and 0.01% w/v sodium azide) was applied onto sections and incubated overnight 
at room temperature. CD31 and GFAP were detected with the donkey anti-mouse Alexa 
Fluor 488 (Life Technologies, Warrington, UK) and TSPO was detected with secondary 
biotinylated anti-goat antibodies (Vector Labs, Burlingame, CA, USA) and a complex of 
biotin and streptavidin conjugated Alexa Fluor 546 (Life technologies). Secondary antibodies 
were incubated for 45 minutes and the avidin-biotin complex for 1 hour. Sections were then 
incubated with DAPI (Life Technologies) in PBS for 30 minutes, rinsed 3 times and 
coverslipped using mountant for fluorescence microscopy (DAKO). Images were 
ascertained by fluorescent microscopy using the LEICA TCS SP5 II confocal microscope 
with integrated application suite (Version: 2.5.2.6939; Leica Microsystems GmbH, Wetzlar, 
Germany).  
Three-dimensional (3D) reconstructions of cortical and white matter vessels and 3D 
analysis of vascular TSPO were performed using a method previously described 33. Full 
details of the procedure are reported in the supplementary materials. 
Distribution analysis of the TSPO and the ubiquitous CD31 was also performed using 
the Bitplane Imaris 3D/4D imaging software (Bitplane AG Zurich, Switzerland). 3D images 
were cropped using the crop 3D tool to form a 500um3 section. For effective analysis of 
stained volume in Imaris the voxel size of the 3D image must be consistent with that of the 
original scanned slides. To achieve this, measurements were made upon the slides' 
localised viewpoints in Caseviewer and an x and y value obtained by dividing Caseviewer’s 
horizontal and vertical image size values by the number of pixels; identified by ImageJ. Z 
values were obtained using the thickness of each original tissue slice, in this case 6μm. 
TSPO expression was calculated by carefully overlaying the TSPO staining with CD31 in 
order to select only vascular TSPO rather than tissue microglia. Perivascular macrophages 
were too close to the vessel walls to be excluded from quantification. In this respect, the 
TSPO volumes in vessels were slightly overestimated. 
11 
 
Identification of the TSPO and CD31 stained surfaces was refined in Imaris using 
background thresholding once images were cropped to the three distinct 500μm3 ROI. 
Whilst background intensity of the images had been adjusted previously, the Imaris surface 
editing tool requires adjustment once again at this point at the discretion of the data analyser. 
Once surfaces were identified the Imaris vantage tool was used to attain values of the two 
stained surfaces such that ROI volumes ratios between the TSPO and CD31 stacks were 
conserved. Results were analysed with a one-way ANOVA with Dunnett’s post-hoc tests, 
performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San 
Diego California USA, www.graphpad.com). 
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RESULTS 
 
Tracer Dosing and Experimental Variables 
We observed no difference in the injected doses between baseline scans (mean±SD: 
321±32 MBq) and blocking scans (mean±SD: 302±75 MBq). In contrast, injected mass 
(BASELINE mean±SD: 2.2±0.6 μg; BLOCKING mean±SD: 4.1±2.1 μg) and specific activity 
(BASELINE mean±SD: 53.7±13.7 GBq/μmol; BLOCKING mean±SD: 32.7±14.6 GBq/μmol) 
were significantly different between conditions. Analyses refer to two-tailed paired t-tests, 
with the p-value=0.05 set as the threshold for significance. 
Motion statistics were comparable between conditions (total motion baseline = 
15.5±7.1mm; total motion follow-up = 12.4±3.9mm; two-tailed paired t-test p-value = 0.42) 
and consistent with an age-matched independent dataset of [11C]PBR28 brain PET scans 
of healthy volunteers 21 (total motion healthy controls = 14.6±4.4mm; two-samples t-test p-
value = 0.27). 
 
Blood data analysis 
Arterial whole blood and plasma activities were significantly affected by XBD173 
administration, compared to baseline conditions (Figure 1). Peak activities and area under 
the curve (AUC)for both plasma (Cp) and whole blood (Cb) TACs significantly increased in 
the second scan, with mean±SD relative differences of 84±79% for peak Cp, 30%±33% for 
peak Cb, 58%±29% for AUC Cp, and 58%±29% for AUC Cb. These variations are consistent 
with the reduction of tracer target availability throughout the body, following TSPO blockage 
by XBD173. 
Plasma-over-blood ratios and parent plasma fractions also changed with XBD173 
blocking (Figure 2). There was a statistically significant group effect in the repeated-measure 
ANOVA for both POB (p-value=0.005) and PPf (p-value=0.006), supporting the impact of 
the blocking agent XBD173 on the plasma-blood tracer interaction as well as on [11C]PBR28 
radiometabolite kinetics. The increased POB in the initial phase (ΔPOB10-30min= 35%%±25%) 
as well as the reduced parent fraction in the XBD173 (ΔPPf10-30min= -34%%±17%) likely 
indicated the higher plasma availability of the tracer, given that the TSPO fraction on 
platelets and red cells was reduced by the blocking agent; hence more parent was amenable 
to metabolism and the parent fraction degraded more quickly. 
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Free plasma fraction (𝑓𝑝) showed a high variability between scans (mean±SD relative 
difference: 6%±40%, min variation -19%, max variation +81%), although these differences 
were not significant (two-tailed paired t-test, p-value>0.05). 
 
[11C]PBR brain PET uptake 
The administration of XBD173 led to a generalised reduction of [11C]PBR28 PET 
uptake across the entire brain in all subjects. SUV analysis showed mean±SD relative 
changes of -40%±7% for whole brain, and -44%±8% for cortical grey matter. No region was 
excluded by tracer uptake displacement, including cerebellum (SUV relative difference -
47%%±8%, mean±SD) (Supplementary material – Figure 3). These reductions remained 
significant even when the tracer specific activity was used as a covariate in the analysis 
(ANOVA, p-value=0.02), with no interaction between specific activity and SUV (p-
value=0.97). 
 
[11C]PBR PET kinetic analysis 
Comparison of model performances 
The analysis of the statistical performance of the kinetic models confirmed 2TCM-1K 
to be superior to 2TCM for the description of [11C]PBR28 data after XBD173 blocking at the 
regional level. This finding is consistent with previous applications of [11C]PBR28 in healthy 
and pathological populations 19, 21. The 2TCM-1K provided a better fit of the tissue data in 
83% of the analysed ROIs (Figure 3). Note that the regions for which 2TCM outperformed 
2TCM-1K were all concentrated in a unique subject, for which we noted different [11C]PBR28 
kinetics compared to the other subjects (Supplementary material – Figure 4). The relative 
difference of the weighted residual sum of squares obtained with 2TCM-1K, compared to 
the 2TCM one, was -39%±23% (mean±SD). Weighted residuals obtained with 2TCM-1K 
were consistent with the assumptions on the measurement error (random and uncorrelated) 
but not those obtained with the 2TCM. 
In terms of parsimony criteria, the AIC for the 2TCM-1K AIC model was smaller than 
2TCM AIC in 75.1% of the regions where both models successfully converged to a 
physiological solution, thus confirming the identification of 2TCM-1K as the optimal model 
to describe [11C]PBR28 brain data (Supplementary Material – Table 1).  
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In term of outliers the two models performed similarly (brain outlier fraction: 12% for 
2TCM and 10% for 2TMC-1K). These were concentrated particularly in small regions 
(average volume <3 cm3) necessarily characterized by high noise data. After correction for 
outliers, individual 𝑉𝑇 estimate precisions were consistent for both models: for 2TCM CV 
𝑉𝑇𝑉𝑇= 9%±9%; for 2TCM-1K CV 𝑉𝑇= 8%±7%.  
 
Kinetic estimates 
The results of [11C]PBR28 PET data quantification using 2TCM-1K and 2TCM models 
are reported in Supplementary Material - Table 2 and 3, respectively. In 2TCM-1K, mean 
parameter estimates for 𝑉𝑇 and 𝑘3 𝑘4⁄  reduced from baseline to blocking in all the ROIs (-
60%±24% for 𝑉𝑇; -71%±23% for 𝑘3 𝑘4⁄ ) (Figure 4A). The non-displaceable component 𝐾1 𝑘2⁄ , 
instead, showed lesser variations (-14%±48%) and even slightly increased in some ROIs 
like amygdala and thalamus (Figure 4A). Changes of the endothelial bound fraction were 
also consistent with the administration of TSPO blocking agent, with a mean reduction 
ranging between 48% to 65% (Supplementary material - Table 4). In term of absolute values, 
the highest changes were detected in the specific compartment (𝑘3 𝑘4⁄  mrd%: -86% to -
26%). These values were highly correlated with 𝑉𝑇 changes (Pearson’s r = 0.85). In contrast 
the lowest changes were detected in the non-displaceable compartment (𝐾1 𝑘2⁄  mrd%: -21% 
to +15%). 
In the case of the 2TCM the parameter estimates for 𝑉𝑇, 𝐾1 𝑘2⁄  and 𝑘3 𝑘4⁄  were 
reduced after XBD173 administration but the relative relationship was different compared to 
2TCM-1K (Figure 4B). The highest variations were detected for 𝑉𝑇 estimates (𝑉𝑇 mrd%: -
76%:-43%), followed by the non-displaceable compartment (𝐾1 𝑘2⁄  mrd%: -53% to -36%). 
The specific compartment estimates, instead, showed quite a variable behaviour (𝑘3 𝑘4⁄  
mrd%: -60% to -5%), but were still correlated with 𝑉𝑇 changes (Pearson’s r = 0.85).  
Notably, while 𝑉𝑇 variations are comparable between models (Two-tailed Paired t-test 
p>0.1), 𝐾1 𝑘2⁄  and 𝑘3 𝑘4⁄  changes due to XBD173 are not (Two-tailed Paired t-test p<0.001). 
These variations in the specific and nonspecific compartments for both 2TCM and 2TCM-
1K are consistent with the model compartmentalisation of the total PET tracer uptake when 
fitting the data (Figure 3). The major differences are visible in blocking condition: while in 
the 2TCM-1K the specific compartment activity becomes negligible compared to the total 
signal, in 2TCM it assumes an almost irreversible kinetic in order to fit the last part of the 
measured data. 
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No difference was detected for blood volume estimates (𝑉𝑏) between baseline-
blocking conditions or models (𝑉𝑏 mean±SD: 0.05±0.01). No significant correlation was 
found between either injected mass or specific activity changes and the variations of any of 
the parameters of interest (i.e. 𝑉𝑇, 𝐾1 𝑘2⁄  or 𝑘3 𝑘4⁄ ) for both 2TCM and 2TCM-1K models. 
Given the absence of any significant relation with the kinetic model parameters, injected 
mass and specific activity effects were discarded from further analysis. 
In term of between-subject variability 2TCM performed better compared to 2TCM-1K 
only for ∆𝐾1 𝑘2⁄  while returned higher CV for ∆𝑘3 𝑘4⁄ . No difference was found for CV ∆𝑉𝑇 (p-
value=0.06). With 2TCM inter-subject CVs were 6% for ∆𝑉𝑇, 5% for ∆𝐾1 𝑘2⁄  and 11% for 
∆𝑘3 𝑘4⁄ . With 2TCM-1K inter-subject CVs were 9% for ∆𝑉𝑇, 20% for ∆𝐾1 𝑘2⁄ , 5% for ∆𝑘3 𝑘4⁄  
and 9% for ∆𝐾𝑏.  
Analysis of model parameter covariance showed some differences between 
models when compared across subjects and ROIs. Correlation between 𝑲𝟏 𝒌𝟐⁄  and 𝑽𝑻 
was 0.2±0.1 for 2TCM and 0.7±0.1 for 2TCM-1K.  Correlation between 𝒌𝟑 𝒌𝟒⁄  and 𝑽𝑻 was 
0.6±0.1 for 2TCM and 0.5±0.3 for 2TCM-1K. 2TCM-1K 𝑲𝒃, instead, inversely correlated 
with all the other model parameters: -0.7±0.2 with 𝑽𝑻, -0.6±0.2 with 𝑲𝟏 𝒌𝟐⁄  and -0.1±0.3 
with 𝒌𝟑 𝒌𝟒⁄ . Results refer to Pearson’s correlation coefficient r. 
 
Relationship between TSPO mRNA expression and kinetic estimates 
With 2TCM-1K, the variations of 𝑉𝑇 and 𝐾𝑏 estimates due to XBD173 blockage were 
significantly correlated with TSPO mRNA expression (adjusted R2: 0.84, p-value<0.01 for 
𝑉𝑇;0.68, p-value<0.01 for 𝐾𝑏) while 2TCM 𝑉𝑇 changes were not (adjusted R
2: 0.15, p-
value=0.21). Comparison of the two models vs. mRNA TSPO expression is reported in 
supplementary material – Figure 5. 
Notably, SUV variations were statistically correlated with TSPO mRNA expression 
but to a lesser extent compared to kinetic estimates (adjusted R2: 0.28, p-value=0.04). 
 
Microscopic analysis of TSPO in vessels 
We investigated the extent of TSPO expression in cortical and white matter vessel in 
the frontal lobe and cerebellum of three normal post-mortem brains. Immunoperoxidase 
immunohistochemistry analysis showed widespread TSPO expression across all brain 
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regions and in both the grey and white matter. Small arteries, arterioles, veins and venules 
appeared to express higher TSPO than capillaries. As previously shown 17, the TSPO was 
seen in both the endothelium and smooth muscle cells of the tunica media. Perivascular 
macrophages were also positive (Figure 5A). Double immunofluorescence confirmed the 
endothelial and smooth muscle cells expression of TSPO and showed that perivascular 
astrocytes, and their end-feed in particular were negative (Figure 5B,C).  
In order to provide a more accurate estimate of vascular TSPO that could be 
translated into imaging studies, we used a 3D approach (Figures 6). Three dimensional 
analysis of cortex and white matter of both the frontal lobe and cerebellum showed patchy 
TSPO expression along vessels accounting for 30% of the vascular volume in cortex and 
white matter. Though not prominent in the sections used for 3D analysis, perivascular 
macrophages could not be excluded from measurement and therefore contributed to the 
overall volume of vascular TSPO, which was therefore slightly overestimated. We also found 
that the vasculature of the cerebellar white matter was denser than the frontal lobe white 
matter and that TSPO expression was therefore higher (Figure 7A-C and Supplementary 
material - Table 5). This result was confirmed by mRNA analysis from Allen Human Brain 
Atlas (Figure 7D). 
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DISCUSSION 
In this study, we provided additional validation for the 2TCM-1K kinetic model for the 
quantification of [11C]PBR28 PET data. When applied to data obtained after XBD173 
administration, the 2TCM-1K produced the expected large changes in the concentration of 
the specific tissue compartment and vascular TSPO availability while changes in the non-
displaceable compartment were negligible. By contrast, most of the changes in 
concentration in the standard 2TCM were in the non-displaceable compartment indicating 
the unsuitability of this model to accurately describe the kinetics induced by the reduction of 
TSPO density. This finding is consistent with previous applications of [11C]PBR28 in healthy 
individuals and patients with CNS diseases 19, 21, showing that 2TCM-1K leads to a better 
and more efficient data description (improved fit and lower Akaike coefficient) compared to 
standard 2TCM. Moreover, the 2TCM-1K has also been shown to be more sensitive to 
changes in affinity as demonstrated by its better sensitivity to changes in rs6971 
polymorphism 19. Our results also extend previous findings that 2TCM-1K binding estimates 
are in better agreement with TSPO mRNA expression than those provided by 2TCM; this 
was demonstrated both in terms of binding data at baseline 19 and here in terms of 
displacement. 
This study analysed [11C]PBR28 binding and proposed the 2TCM-1K model in 
subjects with schizophrenia. Previous work by Kreczmanski and colleagues showed no 
overt differences in the density of cortical capillaries between normal brains and brains with 
schizophrenia 34 suggesting that results obtained in this study can be extended to normal 
subjects. Moreover, although these results were obtained with [11C]PBR28, we expect the 
2TCM-1K to be applicable to other second-generation TSPO tracers. A similar data 
description to that provided by 2TCM-1K for [11C]PBR28 brain PET data has already been 
reported in literature for [11C]PK11195 using spectral analysis (see Figure 5 in 17), while 
preliminary results with [18F]DPA-714 PET highlight the need to account for the vascular 
binding when fitting the data 35.  
In order to further investigate the assumption of a vascular binding component in the 
2TCM-1K model, we performed immunohistochemistry for the endothelial adhesion 
molecule PECAM-1 (CD31) and TSPO. Results confirmed previous studies showing TSPO 
expression in the endothelium and tunica media of leptomeningeal, cortical and white matter 
vessels 36, 37. Saturation binding studies and immunohistochemical studies have confirmed 
it in different conditions 38-41. No data is available on expression in pericytes. In the brain the 
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vessels are surrounded by astrocytic end feet, which are tightly attached to the wall. Double 
immunofluorescence experiments in our study did not demonstrate any TSPO in 
perivascular astrocytes.  
Quantification of PET signal is based on 3D evaluation (voxel) while 
immunohistochemistry on tissue sections gives a bi-dimensional (pixel) of TSPO 
localisation. To further validate PET imaging data, we built 3D immunohistochemistry 
images of cortical and white matter vessels, (volume comparable to imaging voxels) and 
quantified TSPO expression related to the volume of vessels as a surrogate measure of 
vascular TSPO density. TSPO expression was discontinuous but present in all vessels and 
accounting for 30% of the vascular network. This result is agreement with preclinical findings 
showing that TSPO expression in endothelial cells is comparable with the one of microglia 
(Supplementary Material – Figure 6) 42. Our data also showed that the ratio of TSPO and 
vessel volume remains similar in the cortex and grey matter but the absolute expression of 
vascular TSPO in the cerebellar white matter appeared higher than the other regions due to 
the higher vessel density per volume unit. These results were confirmed by [11C]PBR28 PET 
data analysis: compared to cerebellar grey matter, 2TCM-1K endothelial binding statistically 
increased (mean±SD across subjects: 7%±6%) when cerebellar white matter was included 
in the analysis (Two-tailed paired t-test p-value<0.01). It follows that TSPO PET data 
analysis of cerebellum needs to account for its complex cellular heterogeneity. This 
characteristic together with the observed high TSPO displacement does not make the 
cerebellum an ideal reference region for TSPO PET imaging studies. 
The adult brain microvasculature has an overall surface area of about 100 cm2/g 
tissue with an overall volume of capillaries accounting for about 200 cm3 of an average total 
brain volume of 1,200 cm3 43. With such density of blood vessels, and such high endothelial 
TSPO expression, the widespread vascular TSPO documented in our study explains the 
diffuse rather than discrete signal of vascular TSPO, which is high in the cortex and it is 
often interpreted as the result of nonspecific binding. It is worth remembering that vascular 
supply in the normal brain is not uniform across regions and that changes occur in ageing 
and pathological conditions. There is evidence of a reduction of vessel density in aging with 
an overall average decrease of 16% in capillary density and a decline in the density of white 
matter vessels between the fifth and ninth decades. Mann et al. found a decrease in vessel 
density in frontal cortex, but not in the temporal cortex 44. In addition, small vessel disease 
including hyalinization of the wall with loss of smooth muscle cells also impacts on TSPO 
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expression. Robust and reproducible modelling of vascular TSPO is therefore relevant to 
the interpretation of data from normal subjects and patients with brain diseases. 
The evidence provided in our study supports the 2TCM-1K compartmentalization. 
Beyond the relevance for PET quantification, the pharmacokinetics of these compartments 
indicates that the targeting of TSPO in microglia is not a trivial task as a significant 
percentage of TSPO compounds will bind to the vessels and produce an unknown/unwanted 
modulatory effects on the BBB. To this extent, is important to note that using endothelial 
cells derived from human umbilical vein 38, documented TSPO upregulation following 
stimulation with TNF. Overexpression of TSPO in adenovirus transfected cells resulted in 
protection against TNF-induced endothelial activation including inhibition of VCAM-1 and 
ICAM-1 expression, resulting in reduced monocyte adhesion, inhibition of ROS production, 
decrease of mitochondrial manganese superoxide dismutase and downregulation of the 
Voltage Dependent Anion Channel-1 38. In contrast, these results suggest that a reduction 
of TSPO may increase the permeability of the BBB and trafficking of inflammatory cells.  
The dynamics we observed in the blood following XBD173 modulation were also of 
interest. Quantification of PET ligands using arterial input function is regarded as the best 
quantitative measure but it is based on the assumption that the parent plasma concentration 
of the tracer is correct. In this study we observed variable kinetic in the various TSPO blood 
compartments. Owen and colleagues proposed the use of blocking studies, like XBD173, to 
confirm whether 𝑉𝑇 global changes are driven by TSPO-specific signal changes 
9. Our 
results do not support the use of this methodology as the administration of TSPO blocking 
agents such as XBD173 has a significant impact on [11C]PBR28 binding in blood itself and 
seems to alter the plasma free fractions therefore reducing, and not improving, the accuracy 
of the brain measures.  
One key aspect of the complexity of [11C]PBR28 kinetics is the apparent difference 
between the reversible binding profile of the tracer to the parenchima and the irreversible 
binding to the endothelium. Previously we explained this difference in terms of varying 
reactive volumes, which means that while it is the free plasma concentration of the tracer 
that exchanges with endothelial TSPO, only the free fraction in tissue reaches the 
mitochondria exchanges with TSPO in microglia and astrocytes. This is not properly 
modelled by the one only compartment of the 2TCM model where the free tracer 
concentration in reality is the average of a likely steep gradient of concentration, decreasing 
from the blood-brain barrier to the intracellular space and mitochondria 45. Please note that 
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the affinity for TSPO of PBR28 is very high, 4 nmol/L 8 which then translates in the 90 mins 
of the experimental time into apparent irreversibility. Moreover, modelling the endothelial 
tracer binding with a reversible exchange together with a 2-tissue compartmental model 
description does not guarantee the model parameter identifiability (Supplementary material 
- “Study of a priori identifiability of 2TCM-2K model”). 
 
Limitations  
 This work presents some limitations. The blocking studies were performed 2 years 
after the baseline for 6 out of 7 patients of the dataset. The presence of disease as well as 
the well-known interaction between treatment and TSPO density 46 do not allow to assume 
that the level of inflammations remained the same between the two scans. One should 
however note that inflammation in these cohorts resulted in <10% TSPO density increase 
on average in these patient cohorts 21, 47; hence we did not expect that any change in TSPO 
due to modulation of inflammation by disease or treatment would alter substantially the 
displacement of TSPO that in overall was greater than 50%.  
In this experimental design only one structural MRI scan at baseline was performed. 
The procedure might be suboptimal due to the presence of brain changes over time that are 
expected patients with schizophrenia 48 as well as in healthy adults 49. However, we expect 
minimum impact of structural changes on our results as the MRI was only used to assist 
with atlas coregistration to PET images, and our analysis was limited to large regions of 
interest. 
 The use of microparameter ratios (i.e. 𝐾1 𝑘2⁄  and 𝑘3 𝑘4⁄ ) as proxy of the 
nondisplaceable distribution volume and tracer binding potential is penalised by higher 
sensitivity to noise compared to 𝑉𝑇 estimates. However, the ratios 𝐾1 𝑘2⁄  and 𝑘3 𝑘4⁄  are not 
used as group metrics in a cross-sectional design but only as metrics of performance for 
competing kinetic models; here the expected reduced availability of TSPO due to drug 
occupancy should be translated into changes of the specific bound compartment. From a 
theoretical perspective, 𝐾1 𝑘2⁄  ratio should be constant throughout the brain ROIs in 
both baseline and blocking studies; since the aim of the study was the investigation 
of the compartmental structure for this tracer, this ratio was not fixed during the 
optimization and we did notice significant variability across brain. To note that 
microparameters have general validity in quantification 50, 51. Importantly, microparameters 
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and compartmental models are the key to make predictions and guide tracer development 
and this has been particularly the case for TSPO ligands, where previous synthetic work 
using the standard 2TCM model has not been supported by data in-vivo 52. In general 
terms, the kinetic components in compartmental modelling are not orthogonal (by 
definition as the exponential base is not orthogonal) hence substantial covariance 
across microparameters is expected. In the case of the 2TCM1K, 𝑲𝒃 is inversely 
correlated with all the parenchyma components (𝑽𝑻, 𝑲𝟏/𝒌𝟐 and 𝒌𝟑/𝒌𝟒) as they are 
biologically contrasted; the more tracer is associated to vascular binding the less is 
available to the tissue for both specific and non-displaceable binding. 
 The use of TSPO mRNA as proxy of TSPO protein density also needs to be critically 
considered: mRNA is an indicator of gene regulation but not necessarily of protein 
expression 31. Moreover, TSPO mRNA expressions from Allen Brain Atlas do not distinguish 
the cellular source of TSPO (glial or vascular). However, we found good correlation between 
kinetic parameter changes following XBD173 administration and TSPO mRNA, despite the 
fact that the imaging dataset refers to patients with schizophrenia while the mRNA atlas to 
healthy controls. TSPO density increased in SCHZ patients have shown to be limited 21, 47, 
hence the changes observed were mostly due to TSPO density unrelated to the disorder. 
 
Conclusions 
In conclusion, we demonstrated that the accounting for endothelial TSPO gives a 
more precise and accurate quantification of [11C]PBR28 brain PET data that is consistent 
with TSPO biology. TSPO expression in vessels using 3D reconstructions of histological 
data of frontal lobe and cerebellum demonstrates that TSPO positive vessels account for 
30% of the vascular volume in cortical and white matter. 
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FIGURE LEGENDS 
 
Figure 1 – Effect of XBD173 on [11C]PBR28 arterial input functions. [11C]PBR28 kinetics 
in arterial parent plasma (A) and whole blood (B) are reported for a representative subject 
with schizophrenia. For each panel full kinetics (0-90 minutes) and TAC peaks (0-5 minutes) 
are shown. Red lines refer to baseline. Green lines refer to TSPO blocking with 90 mg of 
XBD173.  
Figure 2 – Effect of XBD173 on [11C]PBR28blood metabolism. [11C]PBR28 plasma-over-
blood ratio (POB) and parent plasma fraction (PPf) are reported for a representative subject 
with schizophrenia (panel A and B, respectively). Red samples refer to baseline. Green 
samples refer to TSPO blocking with 90 mg of XBD173. 
Figure 3 – [11C]PBR28 brain PET data fit and model compartmentalisation. Example of 
model fits to whole brain activity with 2TCM-1K (A) and standard 2TCM (B). Data belong to 
a representative subject with schizophrenia, investigated at baseline conditions and after 
XBD173 blocking. For each panel black circles represent measured activity curve while solid 
black lines represent the model description. Single compartmental kinetics are also reported, 
with blue, green and red lines representing non-displaceable, specific and endothelial 
binding, respectively.  
Figure 4 – Effect of XBD173 on [11C]PBR28brain PET kinetic estimates. Percentage 
changes of model kinetic parameter estimates between baseline and XBD173 blockage for 
2TCM-1K (A) and standard 2TCM (B). Mean±SD across 7 subjects with schizophrenia are 
reported in several ROIs. Blue bars indicate 𝑉𝑇 changes. Red bars indicate non-displaceable 
compartment changes (measured as 𝐾1 𝑘2⁄ ). Green bars indicate specific binding changes 
(measured as 𝑘3 𝑘4⁄ ). Purple bars indicate𝐾𝑏 changes. 
Figure 5 - Expression of TSPO in a tissue section of frontal lobe - TSPO is expressed 
in endothelium and tunica media of cortical and white matter vessels including arteries, 
veins, arterioles and venuoles. TSPO is also expressed in blood mononucleated cells and 
perivascular macrophages. The sum of these components contribute to the vascular 
component of the 2TCM-1K model. At the same time, tissue microglia are also TSPO 
positive representing the tissue component of the both 2TCM and 2TCM-1K models (A, 
TSPO immunoperoxidase – x20); confocal double immunofluorescence demonstrates 
TSPO expression in endothelium but the two molecule do not co-localise, the TSPO being 
a mitochondrial protein and CD31 (PECAM-1) an adhesion molecule on the cell surface (B, 
28 
 
double immunofluorescence, CD31 red; TSPO green; nuclear counterstaining with DAPI, 
blue – x20); perivascular reactive astrocytes and their end feed do not express TSPO (C, 
double immunofluorescence, TSPO red; GFAP green; nuclear counterstaining with DAPI, 
blue – x20) 
Figure 6 - Vascular network and vascular TSPO in a cerebellar folium - Three 
dimensional reconstruction of vessels and TSPO expression in a cerebellar folium using 
serial sections immunostained for CD31 (endothelium) and TSPO (A, CD31 red; B, TSPO 
green); localisation of TSPO in endothelial cells is demonstrated in a magnified 250 μm3 
volume of a region at the junction between cortex and white matter (C, CD31 red; TSPO 
green; co-localisation appears in yellow). The insets in images A and B indicate the region 
magnified in C. (GM: grey matter; WM: white matter)  
Figure 7 - Variation of vascular TSPO in tissue 3D model – Three dimensional 
reconstruction of vessels and TSPO expression in a Frontal Lobe (A) and Cerebellum (B) 
using serial sections immunostained for CD31 (endothelium) and TSPO (CD31 red; TSPO 
green). C) Graphical representation of the density of the whole vascular network and TSPO 
positive vessels per volume units of 500 μm3 in the cortex and white matter of frontal lobe 
and cerebellum; the values are calculated in three different regions of interest. D) CD31 
(red) and TSPO (green) mRNA expression as derived by Allen Human brain atlas 
(mean±SD across 6 donors); notably, the ratio between CD31 and TSPO mRNA expression 
(blue) results constant across brain ROIs (mean±SD: 1.23±0.07). 
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